Cited by 892Cancer Cells and MetastasisAcute Lymphoblastic Leukemia researchDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.

Environment-mediated drug resistance: a major contributor to minimal residual disease

Meads, Mark B., Gatenby, Robert A., Dalton, William S.·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Environment-mediated drug resistance is a form of de novo drug resistance that protects tumour cells from the initial effects of diverse therapies. Surviving foci of residual disease can then develop complex and permanent acquired resistance in response to the selective pressure of therapy. Recent evidence indicates that environment-mediated drug resistance arises from an adaptive, reciprocal signalling dialogue between tumour cells and the surrounding microenvironment. We propose that new therapeutic strategies targeting this interaction should be applied during initial treatment to prevent the emergence of acquired resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc2714

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Treatment of Acute Lymphoblastic Leukemia
Pui, C., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 2,012
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G. W., Davé, S. S., Xiao, W., Powell, J. I., Zhao, H., Xu, W., Tan, B. T., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,847
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Ömeroğlu, G., Meterissian, S. H., Ömeroğlu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,707
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citation
Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,380
DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333

Show all 109 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 401–500 of 892

Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
Bartucci, M., Ferrari, A. C., Kim, I. Y., Ploß, A., Yarmush, M. L., & Sabaawy, H. E. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00064 · Cited by 31
Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429
Guo, Q., Lu, L., Liao, Y., Wang, X., Zhang, Y., Liu, Y., Huang, S., Sun, H., Li, Z., & Zhao, L. (2018) · Cell Death and Disease · doi:10.1038/cddis.2017.367 · Cited by 31
Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice
Bartucci, M., Ferrari, A. C., Kim, I. Y., Ploß, A., Yarmush, M. L., & Sabaawy, H. E. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00074 · Cited by 31
Dynamic hydrogel mechanics in organoid engineering: From matrix design to translational paradigms
Zhang, C., Shen, Y. C., Huang, M.-Y., Wang, G., Miao, Q., Shi, H., Gao, R., Wang, K., & Luo, M. B. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.09.021 · Cited by 43
Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia
Liu, J., Masurekar, A. N., Johnson, S. M., Chakraborty, S., Griffiths, J., Smith, D. L., Alexander, S., Dempsey, C. E., Parker, C. A., Harrison, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5528 · Cited by 30
Reciprocal Reprogramming of Cancer Cells and Associated Mesenchymal Stem Cells in Gastric Cancer
Shamai, Y., Cohn-Alperovich, D., Zohar Yakhini, B., Skorecki, K. L., & Tzukerman, M. (2018) · Stem Cells · doi:10.1002/stem.2942 · Cited by 29
Tumour immune microenvironment biomarkers predicting cytotoxic chemotherapy efficacy in colorectal cancer
Wilkinson, K. J., Ng, W. L., Roberts, T. L., Becker, T. M., Lim, S. H.-S., Chua, W. M., & Lee, C. S. (2021) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2020-207309 · Cited by 31
Targeted Removal of Migratory Tumor Cells by Functionalized Magnetic Nanoparticles Impedes Metastasis and Tumor Progression
Scarberry, K. E., Mezencev, R., & McDonald, J. F. (2010) · Nanomedicine · doi:10.2217/nnm.10.103 · Cited by 30
The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies
El‐Daly, S. M., Bayraktar, R., Anfossi, S., & Călin, G. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093387 · Cited by 31
Endothelial cells: major players in acute myeloid leukaemia
Fodil, S., Arnaud, M., Vaganay, C., Puissant, A., Lengliné, É., Mooney, N., Itzykson, R., & Zafrani, L. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100932 · Cited by 29
Discovery of a drug targeting microenvironmental support for lymphoma cells by screening using patient-derived xenograft cells
Sugimoto, K., Hayakawa, F., Shimada, S., Morishita, T., Shimada, K., Katakai, T., Tomita, A., Kiyoi, H., & Naoe, T. (2015) · Scientific Reports · doi:10.1038/srep13054 · Cited by 29
Reversing cancer multidrug resistance: insights into the efflux by ABC transports from in silico studies
Ferreira, R. J., Ferreira, M. U., & dos Santos, D. J. V. A. (2014) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1196 · Cited by 30
Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride
Chen, Y., Li, Z.-Z., Ye, Y., Xu, F., Niu, R., Zhang, H., Zhang, Y., Liu, Y., & Han, B. (2016) · BMC Molecular Biology · doi:10.1186/s12867-016-0055-y · Cited by 30
Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumors
Alaimo, A., Lorenzoni, M., Ambrosino, P., Bertossi, A., Bisio, A., Macchia, A., Zoni, E., Genovesi, S., Cambuli, F., Foletto, V., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03256-5 · Cited by 29
Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
Suzuki, K., Nishiwaki, K., & Yano, S. (2021) · Cancers · doi:10.3390/cancers13020215 · Cited by 28
Sensitivity to Cisplatin in Head and Neck Cancer Cells Is Significantly Affected by Patient-Derived Cancer-Associated Fibroblasts
Peltanová, B., Liskova, M., Gumulec, J., Raudenská, M., Polanska, H. H., Vaculovič, T., Kalfeřt, D., Grega, M., Plzák, J., Betka, J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041912 · Cited by 29
Post-transcriptional repression of circadian component CLOCK regulates cancer-stemness in murine breast cancer cells
Ogino, T., Matsunaga, N., Tanaka, T., Tanihara, T., Terajima, H., Yoshitane, H., Fukada, Y., Tsuruta, A., Koyanagi, S., & Ohdo, S. (2021) · eLife · doi:10.7554/elife.66155 · Cited by 30
The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK
Yu, M., Xu, C., Zhang, H., Lun, J., Wang, L., Zhang, G., & Fang, J. S. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.05.068 · Cited by 29
Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases
Liu, M., Xie, L., Zhang, Y., Chen, J., Zhang, X., Chen, Y., Huang, W., Cai, M., Liang, L., Lai, M., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05550-4 · Cited by 30
Role of mesenchymal cells in the natural history of ovarian cancer: a review
Touboul, C., Vidal, F., Pasquier, J., Lis, R., & Rafii, A. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0271-5 · Cited by 29
Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy
Ragusa, M., Avola, G., Angelica, R., Barbagallo, D., Guglielmino, M. R., Duro, L. R., Majorana, A., Statello, L., Salito, L., Consoli, C., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-377 · Cited by 28
Nanomedicine as a potent strategy in melanoma tumor microenvironment
Pautu, V., Leonetti, D., Lepeltier, É., Clere, N., & Passirani, C. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.014 · Cited by 28
Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells
Song, X.-H., Yang, L., Zheng, X., Zhu, Q., Liao, X.-L., Liu, K., Zhang, W., Peng, Q., Zhu, Y., Zhao, L.-Y., et al. (2023) · MedComm · doi:10.1002/mco2.342 · Cited by 28
Rituximab Treatment Prevents Lymphoma Onset in Gastric Cancer Patient-Derived Xenografts
Corso, S., Cargnelutti, M., Durando, S., Menegon, S., Apicella, M., Migliore, C., Capelôa, T., Ughetto, S., Isella, C., Médico, E., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.02.003 · Cited by 28
Overcoming Chemoresistance in Cancer: The Promise of Crizotinib
Musa, S., Amara, N., Selawi, A., Wang, J., Marchini, C., Agbarya, A., & Mahajna, J. A. (2024) · Cancers · doi:10.3390/cancers16132479 · Cited by 27
The Tumor Microenvironment in Liver Metastases from Colorectal Carcinoma in the Context of the Histologic Growth Patterns
Garcia‐Vicién, G., Mezheyeuski, A., Bañuls, M., Ruiz-Roig, N., & Mollevı́, D. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041544 · Cited by 29
Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2‑STAT1‑Mcl‑1 axis
Li, X., Wang, Z., Zhang, S., Yao, Q., Chen, W., & Liu, F. (2021) · Oncology Letters · doi:10.3892/ol.2021.12613 · Cited by 28
The multifaceted role of Matricellular Proteins in health and cancer, as biomarkers and therapeutic targets
Gopinath, P., Natarajan, A., Sathyanarayanan, A., Veluswami, S., & Gopisetty, G. (2022) · Gene · doi:10.1016/j.gene.2021.146137 · Cited by 26
Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer
Hao, M., Wang, K., Ding, Y., Li, H., Liu, Y., & Ding, L. (2022) · European journal of medical research · doi:10.1186/s40001-022-00759-z · Cited by 30
Drug Resistance: The Role of Exosomal miRNA in the Microenvironment of Hematopoietic Tumors
Cariello, M., Squilla, A., Piacente, M., Venutolo, G., & Fasano, A. (2022) · Molecules · doi:10.3390/molecules28010116 · Cited by 28
Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia
McMahon, K. M., Scielzo, C., Angeloni, N. L., Deiss‐Yehiely, E., Scarfò, L., Ranghetti, P., Ma, S., Kaplan, J. B., Barbaglio, F., Gordon, L. I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14494 · Cited by 27
Perspective: bidirectional exosomal transport between cancer stem cells and their fibroblast-rich microenvironment during metastasis formation
Valcz, G., Buzás, E. I., Szállási, Z., Kalmár, A., Krenács, T., Tulassay, Z., Igaz, P., & Molnár, B. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0071-9 · Cited by 27
The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells
von Rekowski, K. W., König, P., Henze, S., Schlesinger, M., Zawierucha, P., Januchowski, R., & Bendas, G. (2019) · Biomolecules · doi:10.3390/biom9120788 · Cited by 27
The emerging role of miRNA in the perturbation of tumor immune microenvironment in chemoresistance: Therapeutic implications
Mondal, P., Kaur, B., Natesh, J., & Meeran, S. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.04.001 · Cited by 27
Cancer-associated fibroblast exosome LINC00355 promotes epithelial-mesenchymal transition and chemoresistance in colorectal cancer through the miR-34b-5p/CRKL axis
Hu, J., Tang, H., & Wang, Y. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00700-4 · Cited by 26
Association of glioma CD44 expression with glial dynamics in the tumour microenvironment and patient prognosis
Du, Z., Wang, Y., Liang, J., Gao, S., Cai, X., Yu, Y., Qi, Z., Li, J., Xie, Y., & Wang, Z. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.09.003 · Cited by 27
Controlled Breast Cancer Microarrays for the Deconvolution of Cellular Multilayering and Density Effects upon Drug Responses
Håkanson, M., Kobel, S., Lütolf, M. P., Textor, M., Cukierman, E., & Charnley, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040141 · Cited by 26
Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
Feldhahn, N., Arutyunyan, A., Stoddart, S., Zhang, B., Schmidhuber, S. M., Yi, S.-J., Kim, Y., Groffen, J., & Heisterkamp, N. (2012) · OncoImmunology · doi:10.4161/onci.20249 · Cited by 26
The critical roles of tumor-initiating cells and the lymph node stromal microenvironment in human colorectal cancer extranodal metastasis using a unique humanized orthotopic mouse model
Margolin, D. A., Myers, T., Zhang, X., Bertoni, D. M., Reuter, B., Obokhare, I. D., Borgovan, T., Grimes, C., Green, H., Driscoll, T., et al. (2015) · The FASEB Journal · doi:10.1096/fj.14-268938 · Cited by 26
The Role of the Focal Adhesion Protein PINCH1 for the Radiosensitivity of Adhesion and Suspension Cell Cultures
Sandfort, V., Eke, I., & Cordes, N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013056 · Cited by 26
Next-generation Nanotheranostics Targeting Cancer Stem Cells
Reda, A. M., Hosseiny, S., & El-sherbiny, I. M. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0443 · Cited by 26
Bladder Tumor Heterogeneity: The Impact on Clinical Treatment
Chen, C., Qi, X. J., Cao, Y. W., Wang, Y. H., Yang, X. C., Shao, S. X., & Niu, H. T. (2015) · Urologia Internationalis · doi:10.1159/000370165 · Cited by 27
Improving drug penetration to curb tumor drug resistance
Marcucci, F., & Corti, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.06.004 · Cited by 26
Bioengineering Models for Breast Cancer Research
Guiro, K., & Arinzeh, T. L. (2015) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s29424 · Cited by 25
Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression
Murekatete, B., Shokoohmand, A., McGovern, J., Mohanty, L., Meinert, C., Hollier, B. G., Zippelius, A., Upton, Z., & Kashyap, A. S. (2018) · Scientific Reports · doi:10.1038/s41598-017-19073-4 · Cited by 24
Optimization Of Cancer Treatment Through Overcoming Drug Resistance
Elshimali, Y., Wu, Y., Khaddour, H., Wu, Y., Grădinaru, D., Sukhija, H., CHUNG, S. S., & Vadgama, J. V. (2018) · Journal of Cancer Research and Oncobiology · doi:10.31021/jcro.20181107 · Cited by 25
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
Yen, C., & Hsiao, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113503 · Cited by 25
Focal Adhesion-Chromatin Linkage Controls Tumor Cell Resistance to Radio- and Chemotherapy
Storch, K., & Cordes, N. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/319287 · Cited by 27
Hypoxia upregulates the expression of lncRNA H19 in non-small cell lung cancer cells and induces drug resistance
Li, H., Wang, J., Jin, Y., Lin, J., Gong, L., & Xu, Y. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-1812 · Cited by 24
Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies
Reza, M. S., Hossen, M. A., Harun-Or-Roshid, M., Siddika, M. A., Kabir, M. H., & Mollah, M. N. H. (2022) · Discover Oncology · doi:10.1007/s12672-022-00546-6 · Cited by 24
The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets
Roberto, M., Arrivi, G., Civita, M. A. D., Barchiesi, G., Pilozzi, E., Marchetti, P., Santini, D., Mazzuca, F., & Tomao, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1154581 · Cited by 26
Determining tamoxifen sensitivity using primary breast cancer tissue in collagen-based three-dimensional culture
Leeper, A. D., Farrell, J., Williams, L. J., Thomas, J. S. J., Dixon, J. M., Wedden, S. E., Harrison, D. J., & Katz, E. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.028 · Cited by 24
Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
Eisenberg, D. P., Carpenter, S. G., Adusumilli, P. S., Chan, M.-K., Hendershott, K. J., Yu, Z., & Fong, Y. (2010) · Surgery · doi:10.1016/j.surg.2010.05.005 · Cited by 24
Keeping an open mind: highlights and controversies of the breast cancer stem cell theory
Allegrucci, C., & Shah, M. (2012) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s26434 · Cited by 24
Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer
van Pelt, G. W., Hansen, T. F., Bastiaannet, E., Kjær‐Frifeldt, S., van Krieken, J. H., Tollenaar, R. A. �. �., Sørensen, F. B., & Mesker, W. E. (2016) · Journal of Medical & Surgical Pathology · doi:10.4172/2472-4971.1000116 · Cited by 24
Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism
Aoki, T., Shimada, K., Sakamoto, A., Sugimoto, K., Morishita, T., Kojima, Y., Shimada, S., Kato, S. X., Iriyama, C., Kuno, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14393 · Cited by 24
Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis
Lee, H., Lee, E., Yeo, S.-Y., Shin, S. H., Park, H., Nam, D., & Kim, S. (2018) · Investigational New Drugs · doi:10.1007/s10637-017-0547-8 · Cited by 24
Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment
Alameda, D., Sáez, B., Lara‐Astiaso, D., Sarvide, S., Lasa, M., Alignani, D., Rodríguez, I., Gárate, S., Vilas‐Zornoza, A., Paiva, B., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.235135 · Cited by 24
Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications
Kariya, Y., & Nishita, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073143 · Cited by 24
Rhenium Perrhenate (188ReO4) Induced Apoptosis and Reduced Cancerous Phenotype in Liver Cancer Cells
Asadian, S., Piryaei, A., Gheibi, N., Kalantari, B. A., Davarpanah, M. R., Azad, M., Kapustina, V., Alikhani, M., Nejad, S. M., Alikhani, H. K., et al. (2022) · Cells · doi:10.3390/cells11020305 · Cited by 23
Transforming Growth Factor-Beta Orchestrates Tumour and Bystander Cells in B-Cell Non-Hodgkin Lymphoma
Timmins, M. A., & Ringshausen, I. (2022) · Cancers · doi:10.3390/cancers14071772 · Cited by 24
Le microenvironnement tumoral et la résistance thérapeutique
Borriello, L., & DeClerck, Y. A. (2014) · médecine/sciences · doi:10.1051/medsci/20143004021 · Cited by 23
Bortezomib salvage followed by a P hase I / II study of bortezomib plus high‐dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma
Nishihori, T., Alekshun, T. J., Shain, K. H., Sullivan, D. M., Baz, R., Perez, L. E., Pidala, J., Kharfan‐Dabaja, M. A., Ochoa-Bayona, J. L., Fernandez, H. F., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09099.x · Cited by 22
Self-citation
Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel
Sehrawat, U., Pokhriyal, R., Gupta, A. K., Hariprasad, R., Khan, M. I., Gupta, D., Naru, J., Singh, S. B., Mohanty, A. K., Vanamail, P., et al. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s35775 · Cited by 23
Role of Pericellular Matrix in the Regulation of Cancer Stemness
Avnet, S., & Cortini, M. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9660-x · Cited by 23
Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance
Lifshitz, V., Priceman, S. J., Li, W., Cherryholmes, G. A., Lee, H., Makovski-Silverstein, A., Borriello, L., DeClerck, Y. A., & Yu, H. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0379 · Cited by 24
Adipose-derived mesenchymal stem cells attenuate cisplatin-induced apoptosis in epithelial ovarian cancer cells
Wen, Y., Guo, Y. P., Huang, Z., Cai, J., & Wang, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7783 · Cited by 23
CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance
Coursier, D., & Calvo, F. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00931-z · Cited by 23
Potential Role of PDGFRβ-Associated THBS4 in Colorectal Cancer Development
Kim, M. S., Choi, H. S., Wu, M., Myung, J. Y., Kim, E. J., Kim, Y. S., Ro, S., Ha, S. E., Bartlett, A., Wei, L., et al. (2020) · Cancers · doi:10.3390/cancers12092533 · Cited by 22
MicroRNA-21 and multiple myeloma: small molecule and big function
Ma, J., Liu, S., & Wang, Y. (2014) · Medical Oncology · doi:10.1007/s12032-014-0094-5 · Cited by 22
Aiding and Abetting: How the Tumor Microenvironment Protects Cancer from Chemotherapy
Fiedler, E. C., & Hemann, M. T. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055524 · Cited by 22
Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells
Chen, H.-A., Li, C., Lin, Y., Wang, T.-F., Chen, M., Su, Y., Yeh, Y., Padma, V. V., Liao, P., & Huang, C. (2021) · Aging · doi:10.18632/aging.202908 · Cited by 21
3D Multicellular Tumor Spheroids in a Microfluidic Droplet System for Investigation of Drug Resistance
Lee, S. I., Choi, Y. Y., Kang, S. G., Kim, T. H., Choi, J. W., Kim, Y. J., Kim, T. P., Kang, T., & Chung, B. G. (2022) · Polymers · doi:10.3390/polym14183752 · Cited by 21
Emergence of Anti-Cancer Drug Resistance: Exploring the Importance of the Microenvironmental Niche via a Spatial Model
Gevertz, J. L., Aminzare, Z., Norton, K., Pérez-Velázquez, J., Volkening, A., & Rejniak, K. A. (2015) · The IMA volumes in mathematics and its applications · doi:10.1007/978-1-4939-2782-1_1 · Cited by 21
Evolutionary game theory for physical and biological scientists. II. Population dynamics equations can be associated with interpretations
Liao, D., & Tlsty, T. D. (2014) · Interface Focus · doi:10.1098/rsfs.2014.0038 · Cited by 21
Therapeutically targeting SELF ‐reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?
BERNASCONI, P. P., Farina, M., Boni, M., Dambruoso, I., & Calvello, C. (2016) · American Journal of Hematology · doi:10.1002/ajh.24312 · Cited by 22
A rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemia
Senft, D., & Jeremias, I. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.09.006 · Cited by 23
Elastography of multicellular spheroids using 3D light microscopy
Jaiswal, D., Moscato, Z. M., Tomizawa, Y., Claffey, K. P., & Hoshino, K. (2019) · Biomedical Optics Express · doi:10.1364/boe.10.002409 · Cited by 21
Interleukin-32θ inhibits tumor-promoting effects of macrophage-secreted CCL18 in breast cancer
Pham, T., Bak, Y., Kwon, T., Kwon, S.-B., Oh, J., Park, J.-H., Choi, Y., Hong, J. T., & Yoon, D. (2019) · Cell Communication and Signaling · doi:10.1186/s12964-019-0374-y · Cited by 21
Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression
Pătraș, L., & Banciu, M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190701143845 · Cited by 21
Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma
Allegra, A., Ettari, R., Innao, V., & Bitto, A. (2021) · Cells · doi:10.3390/cells10020448 · Cited by 22
Anti-Cancer Effects of YAP Inhibitor (CA3) in Combination with Sorafenib against Hepatocellular Carcinoma (HCC) in Patient-Derived Multicellular Tumor Spheroid Models (MCTS)
Han, S., Lim, J. Y., Cho, K., Lee, H. W., Park, J. Y., Ro, S. W., Kim, K. S., Seo, H. R., & Kim, D. Y. (2022) · Cancers · doi:10.3390/cancers14112733 · Cited by 20
ATB0,+-targeted nanoparticles initiate autophagy suppression to overcome chemoresistance for enhanced colorectal cancer therapy
Chen, Z., Chen, H., Huang, L., Duan, B., Dai, S., Cai, W., Sun, M., Jiang, Z., Lu, R., Jiang, Y., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123082 · Cited by 20
Optimized Mouse Model for the Imaging of Tumor Metastasis upon Experimental Therapy
Lavilla-Alonso, S., Abo‐Ramadan, U., Halavaara, J. T., Escutenaire, S., Tatlisumak, T., Saksela, K., Kanerva, A., Hemminki, A., & Pesonen, S. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026810 · Cited by 20
Bone marrow stromal cells in the pathogenesis of acute myeloid leukemia
Blau, O. (2014) · Frontiers in bioscience · doi:10.2741/4203 · Cited by 19
Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway
Ji, N., Yu, J., Ni, X., Wu, J., Wang, S., & Jiang, B.-J. (2016) · Tumor Biology · doi:10.1007/s13277-016-5319-0 · Cited by 20
Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives
Zahan, T., Das, P. K., Akter, S. F., Habib, R., Rahman, M. H., Karim, M. R., & Islam, F. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620999200730161829 · Cited by 21
Acid and phosphatase-triggered release and trapping of a prodrug on cancer cell enhance its chemotherapy
Zhu, L., Shen, Z., Liu, X., Tang, R., Zhang, Z., Zhao, F., Wang, J., Zhan, W., Zhou, L., Liang, G., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123254 · Cited by 19
Identifying therapeutic targets in gastric cancer: the current status and future direction
Yu, B., & Xie, J. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv084 · Cited by 19
Lung Adenocarcinoma Mouse Models Based on Orthotopic Transplantation of Syngeneic Tumor-Initiating Cells Expressing EpCAM, SCA-1, and Ly6d
Semba, T., Sato, R., Kasuga, A., Suina, K., Shibata, T., Kohno, T., Suzuki, M., Saya, H., & Arima, Y. (2020) · Cancers · doi:10.3390/cancers12123805 · Cited by 20
Acquired deficiency of peroxisomal dicarboxylic acid catabolism is a metabolic vulnerability in hepatoblastoma
Wang, H., Lu, J. L., Chen, X., Schwalbe, M., Gorka, J. E., Mandel, J. A., Wang, J., Goetzman, E. S., Ranganathan, S., Dobrowolski, S. F., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100283 · Cited by 21
Breast tumour stroma is a prognostic indicator and target for therapy
Howell, A., Landberg, G., & Bergh, J. C. S. (2009) · Breast Cancer Research · doi:10.1186/bcr2435 · Cited by 19
A multiscale model of the bone marrow and hematopoiesis
Silva, A. S., Anderson, A. R. A., & Gatenby, R. A. (2011) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2011.8.643 · Cited by 19
Self-citation
Knockdown of PARP6 or survivin promotes cell apoptosis and inhibits cell invasion of colorectal adenocarcinoma cells
Wang, H., Li, S., Luo, X., Song, Z., Long, X., & Zhu, X. (2017) · Oncology Reports · doi:10.3892/or.2017.5441 · Cited by 19
Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation
Yang, J., Liao, Q., Price, M., Moriarity, B. S., Wolf, N. K., Felices, M., Miller, J. S., Geller, M. A., Bendzick, L. E., Hopps, R., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101318 · Cited by 18
Patient-derived xenograft models for oncology drug discovery
Li, G. (2015) · Journal of Cancer Metastasis and Treatment · doi:10.4103/2394-4722.152769 · Cited by 19
Stem cell technology in breast cancer: current status and potential applications
Chiotaki, R., Polioudaki, H., & Theodoropoulos, P. A. (2016) · Stem Cells and Cloning Advances and Applications · doi:10.2147/sccaa.s72836 · Cited by 18
Nuclear factor-κB activation by transforming growth factor-β1 drives tumour microenvironment-mediated drug resistance in neuroblastoma
Louault, K., Blavier, L., Lee, M., Kennedy, R. J., Fernández, G. E., Pawel, B., Asgharzadeh, S., & DeClerck, Y. A. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02686-8 · Cited by 18
Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?
Szala, S., Mitrus, I., & Sochanik, A. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0873-6 · Cited by 18
Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation
Frazier, J. P., Bertout, J. A., Kerwin, W. S., Moreno‐Gonzalez, A., Casalini, J. R., Grenley, M. O., Beirne, E., Watts, K. L., Keener, A., Thirstrup, D. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0084 · Cited by 18

Authors: Meads, M. B., Gatenby, R. A., & Dalton, W. S.
Affiliations: Moffitt Cancer Center (US)
Corresponding author: Dalton, William S.
ORCID: Meads, Mark B.
Gatenby, Robert A.
Dalton, William S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-08-20
Volume: 9
Issue: 9
Pages: 665-674
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2714
OpenAlex: W2066616821
Cited by: 892
References: 109
Citations by year: 2026: 33 · 2025: 44 · 2024: 35 · 2023: 55 · 2022: 54 · 2021: 74 · 2020: 65 · 2019: 58 · 2018: 56 · 2017: 52 · 2016: 68 · 2015: 61 · 2014: 64 · 2013: 51 · 2012: 52
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: tumor microenvironment, minimal residual disease, recurrence, acquired drug resistance, stromal factors, adjuvant therapy, cancer therapy resistance
MeSH terms: Humans, Neoplasms, Signal Transduction, Stromal Cells, Neoplasm, Residual, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Environment-mediated drug resistance: a major contributor to minimal residual disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks